SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes inspection at Rubicon Research’s R&D facility in Canada

25 Apr 2026 Evaluate

United States Food and Drug Administration (USFDA) has successfully completed an unannounced inspection at Rubicon Research’s R&D facility located at Concord, Ontario, Canada, from April 20, 2026 to April 24, 2026. The inspection concluded without any Form-483 being issued.  

Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.


Rubicon Research Share Price

1294.35 6.65 (0.52%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Wework India Managem 638.55
Rubicon Research 1294.35
Aegis Vopak Terminal 218.15
Mallcom 1018.20
Inducto Steel 50.82
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: